Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2001 Nov 24;323(7323):1218-22.
doi: 10.1136/bmj.323.7323.1218.

Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study

P J Devereaux  1 , D R Anderson, M J Gardner, W Putnam, G J Flowerdew, B F Brownell, S Nagpal, J L Cox
Affiliations
Multicenter Study

Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study

P J Devereaux et al. BMJ. .

Abstract

Objective: To determine and compare physicians' and patients' thresholds for how much reduction in risk of stroke is necessary and how much risk of excess bleeding is acceptable with antithrombotic treatment in people with atrial fibrillation.

Design: Prospective observational study.

Setting: Tertiary and peripheral referral centres in Nova Scotia, Canada.

Participants: 63 physicians who were treating patients with atrial fibrillation and 61 patients at high risk for atrial fibrillation.

Main outcome measures: Participants underwent a face to face interview with a probability trade-off tool. Thresholds were determined for the minimum reduction in risk of stroke necessary and the maximum increase in risk of excess bleeding acceptable for treatment with aspirin and warfarin in people with atrial fibrillation.

Results: The minimum number of strokes that needed to be prevented in 100 patients over two years for warfarin to be justified was significantly lower for patients than for physicians (1.8 (SD 1.9) v 2.5 (1.6), P=0.009), whereas for aspirin there was no difference between patients and physicians (1.3 (1.3) v 1.6 (1.5), P=0.29). The maximum number of excess bleeds acceptable in 100 patients over two years for use of warfarin and aspirin was significantly higher for patients than for physicians (warfarin 17.4 (7.1) v 10.3 (6.1); aspirin 14.7 (8.5) v 6.7 (6.2); P<0.001 for both comparisons).

Conclusions: Patients at high risk for atrial fibrillation placed more value on the avoidance of stroke and less value on the avoidance of bleeding than did physicians who treat patients with atrial fibrillation. The views of the individual patient should be considered when decisions are being made about antithrombotic treatment for people with atrial fibrillation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Example of pictorial flip charts
Figure 2
Figure 2
Recruitment and response rate in patients and physicians
Figure 3
Figure 3
Stroke thresholds for warfarin
Figure 4
Figure 4
Stroke thresholds for aspirin
Figure 5
Figure 5
Bleeding thresholds for warfarin
Figure 6
Figure 6
Bleeding thresholds for aspirin
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cuddy TE, Connolly SJ. Atrial fibrillation and atrial flutter. Can J Cardiol. 1996;(12 suppl A):9–11. - PubMed
    1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22:983–988. - PubMed
    1. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–1457. - PubMed
    1. Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. Arch Intern Med. 1997;157:1237–1240. - PubMed
    1. Connolly SJ. Preventing stroke in atrial fibrillation: why are so many eligible patients not receiving anticoagulant therapy? Can Med Assoc J. 1999;161:533–534. - PMC - PubMed

Publication types

MeSH terms